Health Economics›Non-small cell lung cancer›ALK-mutated, all lines of therapy

ALK-mutated, all lines of therapy

Non-small cell lung cancer · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Crizotinib monotherapy Variant #01	—	R 50 221	28d	~11.1 mo	—	~2	~R 100 441 PFS proxy · indirect	12
Ceritinib monotherapy Variant #01	—	R 35 198	28d	~11.0 mo	—	~2	~R 70 395 PFS proxy · indirect	2
Alectinib monotherapy Variant #01	—	R 108	28d	~27.0 mo	—	~2	~R 215 PFS proxy · indirect	7

3 of 3 regimens shown